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time to hospitalization for CHF were identiﬁed through
a Cox regression model. RESULTS: Mean age at inclu-
sion was 68.6 years and 31.1% of patients were female.
64% had a NYHA class II and 34.4% a NYHA class 
III while 42.4% had a history of MI. Rates of hospital-
ization for CHF ranged from 7.3% (NL) to 10.4% (S).
The Cox model indicated that a patient with the same
clinical characteristics had less chances to be hospitalized
for his CHF in the Netherlands (HR: 0.397; p = 0.003).
Individuals in the Netherlands were also more likely 
than the population as a whole to receive diuretics 
(89% vs. 79%; p = 0.0004), beta blockers (63% vs. 53%;
p < 0.0001), and spironolactone (44% vs. 28%; p <
0.0001). CONCLUSIONS: Some differences in hospital-
ization rates between EU countries were identiﬁed. They
may be related partly to differences in Health care systems
and partly to differences in use of cardiovascular 
medications.
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OBJECTIVE: To determine the 1-year cost of myocardial
infarction and stroke (ﬁrst hospitalization and follow-up)
in Hungary. METHODS: A retrospective patient follow-
up was developed in the National Health Fund Adminis-
tration (NHIFA) Database. Patients were selected by ICD
codes of myocardial infarction and stroke in the database
and were follow-up during one year (2000). All of their
resources consumption and costs reported by hospitals
and outpatient care was registered. Only resource use 
due to myocardial infarction and stroke was collected.
Costing was evaluated from the payer’s (Insurer) per-
spective. Inpatient and outpatient costs were collected.
RESULTS: The average 1-year cost of a myocardial
infarction was 374,086 HUF per patients (255,887 HUF
for acute care and 118,199 HUF for the follow-up) in
2000. The average 1-year cost of a stroke was 122,399
HUF per patient (91,027 HUF for acute care and 31,372
HUF for the follow-up). The estimated costs for year
2003 is 480 185 for the myocardial infarction and
158,059 for stroke. CONCLUSION: There is little infor-
mation about total costs of these pathologies in Hungary.
The methodology of patient follow-up was able to show
the costs paid by Insurer for patients suffering in myocar-
dial infarction and stroke. Costs evaluation allows per-
forming economic evaluation on the ﬁeld in Hungary.
PCV26
COST-EFFECTIVENESS OF EXTENDING
PROPHYLAXIS WITH FONDAPARINUX IN
PREVENTING VENOUS THROMBOEMBOLISM
FOLLOWING HIP FRACTURE SURGERY
van HOUT BA1, Minjoulat-Rey MC2, Quinlan D3,
Theeuwes A4, Gabriel S2
1University of Utrecht, Utrecht, Netherlands; 2Sanoﬁ
Synthelabo Recherche, Bagneux, France; 3King’s College
Hospital, London, United Kingdom; 4Organon, Oos,
Netherlands
OJECTIVES: Patients undergoing hip fracture surgery are
at high risk for postoperative venous thromboembolism
(VTE) with the risk remaining elevated for several weeks.
Fondaparinux, the new synthetic selective factor Xa
inhibitor, is highly efﬁcacious and well-tolerated when
administered for 1 week. Extending prophylaxis for 4
weeks results in an additional reduction in symptomatic
VTE (relative risk reduction 89%, p = 0.02). This signif-
icant efﬁcacy beneﬁt must be weighed against the added
cost of prophylaxis for this period. This study examines
the cost-effectiveness of extending prophylaxis with fon-
daparinux from 1 to 4 weeks among patients undergoing
hip fracture surgery. METHODS: A cohort simulation
model was developed to compare the outcomes and costs
to the UK National Health Service (NHS) of extending
prophylaxis with fondaparinux for 4 weeks compared
with 1 week, up to 5 years. Probabilities for efﬁcacy and
safety outcomes were derived from randomized clinical
trials with fondaparinux, and from a literature review.
Outcomes were symptomatic VTE events (deep-vein
thrombosis, pulmonary embolism), recurrent VTE, post
thrombotic syndrome and death. Resource consequences
were estimated from a survey of UK hospitals and a panel
of clinical experts. Costs were based on mean national
costs to the NHS. Cost per life-year saved was calculated.
RESULTS: Among a cohort of 10,000 patients the use of
fondaparinux for 4 weeks compared with 1 week is esti-
mated to prevent an additional 343 symptomatic VTE 
at 3 months, of which 137 would have been fatal. The
number needed to treat to avoid an additional sympto-
matic VTE event is 30. At 5 years the incremental cost
per patient would be £108 and the cost per life year saved
£1099. CONCLUSIONS: Extending thromboprophy-
laxis with fondaparinux from 1 to 4 weeks following hip
fracture surgery appears to be a cost-effective strategy
with greater clinical beneﬁts achieved and limited addi-
tional costs incurred.
